BIOLASE Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOLASE stock.
View analyst ratings for BIOLASE or view top-rated stocks.

Wall Street analysts have given BIOLASE a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BIOLASE wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

BIOLASE is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for BIOLASE.

BIOLASE, Inc. (NASDAQ:BIOL) issued its quarterly earnings results on Thursday, May, 13th. The medical technology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.01. The medical technology company earned $8.12 million during the quarter. BIOLASE had a negative net margin of 67.89% and a negative trailing twelve-month return on equity of 121.41%.
View BIOLASE's earnings history.

BIOLASE's stock was trading at $0.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIOL stock has increased by 44.0% and is now trading at $0.8353.
View which stocks have been most impacted by COVID-19.

BIOLASE's stock reverse split on Friday, May 11th 2018. The 1-5 reverse split was announced on Thursday, May 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 10th 2018. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 20 shares after the split.

BIOLASE issued an update on its second quarter 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $7.50 million-8.50 million, compared to the consensus revenue estimate of $8.28 million.

2 analysts have issued twelve-month price targets for BIOLASE's shares. Their forecasts range from $1.15 to $2.00. On average, they expect BIOLASE's share price to reach $1.58 in the next year. This suggests a possible upside of 88.6% from the stock's current price.
View analysts' price targets for BIOLASE or view top-rated stocks among Wall Street analysts.

8 employees have rated BIOLASE CEO Todd Norbe on Glassdoor.com. Todd Norbe has an approval rating of 13% among BIOLASE's employees. This puts Todd Norbe in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to BIOLASE include Straumann (SAUHF), Sartorius Aktiengesellschaft (SARTF), DENTSPLY SIRONA (XRAY), Envista (NVST), SmileDirectClub (SDC), American Medical Technologies (ADLI), Lancer Orthodontics (LANZ) and Remedent (REMI).
View all of BIOL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS).

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

BIOLASE's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.38%), Renaissance Technologies LLC (1.48%), Perkins Capital Management Inc. (1.10%), Geode Capital Management LLC (0.79%), Citadel Advisors LLC (0.26%) and Northern Trust Corp (0.18%). Company insiders that own BIOLASE stock include Jack W Schuler, John R Beaver and Larry N Feinberg.
View institutional ownership trends for BIOLASE.

BIOL stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Perkins Capital Management Inc., Citadel Advisors LLC, Millennium Management LLC, Northern Trust Corp, and Goldman Sachs Group Inc.. Company insiders that have bought BIOLASE stock in the last two years include John R Beaver, and Larry N Feinberg.
View insider buying and selling activity for BIOLASE or or view top insider-buying stocks.

Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOL stock can currently be purchased for approximately $0.84.

BIOLASE has a market capitalization of $125.63 million and generates $22.78 million in revenue each year. The medical technology company earns $-16,830,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

BIOLASE employs 135 workers across the globe.

The official website for BIOLASE is www.biolase.com.

BIOLASE is headquartered at 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610.

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The medical technology company can be reached via phone at 949-361-1200 or via email at [email protected]